{
    "id": 64,
    "premise": "none",
    "hypothesis": "If patient has previously received endocrine therapy, they may benefit from treatment with alpelisib-fulvestrant to target PIK3CA mutation.",
    "label": "entailment",
    "explanation": "Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival.\nTreatment with alpelisib\u2013fulvestrant prolonged progression-free survival among patients with\u00a0PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously.\u00a0\nPatient is likely less sensitive to chemotherapy.",
    "results": {
        "semantic validity": false,
        "premise": null,
        "hypothesis": "If patient has previously received endocrine therapy, they may benefit from treatment with alpelisib-fulvestrant to target PIK3CA mutation.",
        "history explanation": [
            "0 iteration: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival.\nTreatment with alpelisib\u2013fulvestrant prolonged progression-free survival among patients with\u00a0PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously.\u00a0\nPatient is likely less sensitive to chemotherapy.",
            "1 iteration: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival.\nTreatment with alpelisib\u2013fulvestrant prolonged progression-free survival among patients with\u00a0PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously.\u00a0\nPatient is likely less sensitive to chemotherapy.",
            "2 iteration: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival.\nTreatment with alpelisib\u2013fulvestrant prolonged progression-free survival among patients with\u00a0PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously.\u00a0\nPatient is likely less sensitive to chemotherapy.",
            "3 iteration: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival.\nTreatment with alpelisib\u2013fulvestrant prolonged progression-free survival among patients with\u00a0PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously.\u00a0\nPatient is likely less sensitive to chemotherapy.",
            "4 iteration: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival.\nTreatment with alpelisib\u2013fulvestrant prolonged progression-free survival among patients with\u00a0PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously.\u00a0\nPatient is likely less sensitive to chemotherapy.",
            "5 iteration: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival.\nTreatment with alpelisib\u2013fulvestrant prolonged progression-free survival among patients with\u00a0PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously.\u00a0\nPatient is likely less sensitive to chemotherapy.",
            "6 iteration: A patient who is less sensitive to chemotherapy is more likely to have previously received endocrine therapy.\nPatients who have received endocrine therapy are more likely to exhibit reduced sensitivity to chemotherapy.",
            "7 iteration: A patient who is less sensitive to chemotherapy is more likely to have previously received endocrine therapy.\nPatients who have received endocrine therapy are more likely to exhibit reduced sensitivity to chemotherapy.",
            "8 iteration: A patient who is less sensitive to chemotherapy is more likely to have previously received endocrine therapy.\nPatients who have received endocrine therapy are more likely to exhibit reduced sensitivity to chemotherapy.",
            "9 iteration: A patient who is less sensitive to chemotherapy is more likely to have previously received endocrine therapy.\nPatients who have received endocrine therapy are more likely to exhibit reduced sensitivity to chemotherapy.",
            "10 iteration: A patient who is less sensitive to chemotherapy is more likely to have previously received endocrine therapy.\nPatients who have received endocrine therapy are more likely to exhibit reduced sensitivity to chemotherapy."
        ],
        "history semantic validity": [
            "0 iteration: False",
            "1 iteration: False",
            "2 iteration: False",
            "3 iteration: False",
            "4 iteration: False",
            "5 iteration: False",
            "6 iteration: False",
            "7 iteration: False",
            "8 iteration: False",
            "9 iteration: False",
            "10 iteration: False"
        ],
        "history critique output": [
            "0 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_64_0\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  KinaseInhibitor :: \"event \u21d2 bool\"\\n  Target :: \"event \u21d2 entity \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 entity \u21d2 bool\"\\n  Proliferation :: \"entity \u21d2 bool\"\\n  Survival :: \"entity \u21d2 bool\"\\n  PI3KAKT :: \"entity\"\\n  \\n(* Explanation 1: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival. *)\\naxiomatization where\\n  explanation_1: \"\u2203e. KinaseInhibitor e \u2227 Target e PI3KAKT \u2227 Inhibit e PI3KAKT Proliferation \u2227 Inhibit e PI3KAKT Survival\"\\n\\nconsts\\n  Treatment :: \"event \u21d2 entity \u21d2 bool\"\\n  Prolong :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"entity \u21d2 bool\"\\n  PIK3CAmutated :: \"entity \u21d2 bool\"\\n  HRpositive :: \"entity \u21d2 bool\"\\n  HER2negative :: \"entity \u21d2 bool\"\\n  AdvancedBreastCancer :: \"entity \u21d2 bool\"\\n  ReceivedEndocrineTherapy :: \"event \u21d2 entity \u21d2 bool\"\\n  AlpelisibFulvestrant :: \"entity\"\\n  \\n(* Explanation 2: Treatment with alpelisib\u2013fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously. *)\\naxiomatization where\\n  explanation_2: \"\u2203e. Treatment e AlpelisibFulvestrant \u2227 Prolong e ProgressionFreeSurvival \u2227 (\u2203x. Patient x \u2227 PIK3CAmutated x \u2227 HRpositive x \u2227 HER2negative x \u2227 AdvancedBreastCancer x \u2227 ReceivedEndocrineTherapy e x)\"\\n\\nconsts\\n  LessSensitive :: \"entity \u21d2 entity \u21d2 bool\"\\n  Chemotherapy :: \"entity\"\\n  \\n(* Explanation 3: A patient is likely less sensitive to chemotherapy. *)\\naxiomatization where\\n  explanation_3: \"\u2203x. Patient x \u2227 LessSensitive x Chemotherapy\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Patient x \u2227 ReceivedEndocrineTherapy e x\"\\n  (* Hypothesis: If a patient has previously received endocrine therapy, they may benefit from treatment with alpelisib-fulvestrant to target PIK3CA mutation. *)\\n shows \"\u2203x e. Patient x \u2227 ReceivedEndocrineTherapy e x \u2227 BenefitFrom e \u2227 Treatment e AlpelisibFulvestrant \u2227 Target e PIK3CA\"\\nproof -\\n  (* From the premise, we know that the patient x has received endocrine therapy e. *)\\n  from asm have \"Patient x \u2227 ReceivedEndocrineTherapy e x\" <ATP>\\n  (* There is a logical relation Implies(B, C), Implies(treatment with alpelisib-fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, patient is likely less sensitive to chemotherapy) *)\\n  (* We can infer that the patient x is likely less sensitive to chemotherapy. *)\\n  then have \"Patient x \u2227 LessSensitive x Chemotherapy\" <ATP>\\n  (* There is a logical relation Implies(Not(C), Not(A)), Implies(Not(patient is likely less sensitive to chemotherapy), Not(using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival)) *)\\n  (* Since the patient x is less sensitive to chemotherapy, we can infer that using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival. *)\\n  then have \"KinaseInhibitor e \u2227 Target e PI3KAKT \u2227 Inhibit e PI3KAKT Proliferation \u2227 Inhibit e PI3KAKT Survival\" <ATP>\\n  (* There is a logical relation Implies(A, C), Implies(using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival, patient is likely less sensitive to chemotherapy) *)\\n  (* We can conclude that the patient x is likely less sensitive to chemotherapy and may benefit from treatment with alpelisib-fulvestrant to target PIK3CA mutation. *)\\n  then have \"\u2203x e. Patient x \u2227 ReceivedEndocrineTherapy e x \u2227 BenefitFrom e \u2227 Treatment e AlpelisibFulvestrant \u2227 Target e PIK3CA\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival\\nB: treatment with alpelisib-fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously\\nC: patient is likely less sensitive to chemotherapy\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival, treatment with alpelisib-fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously)\\n--------\\nImplies(B, C)\\nImplies(treatment with alpelisib-fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, patient is likely less sensitive to chemotherapy)\\n--------\\n\\nDerived Implications:\\nImplies(A, C)\\nImplies(using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival))\\n--------\\n'}",
            "1 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 12.728120803833008, 'proof tactics': ['Type unification failed: Clash of types \"_ \\\\<Rightarrow> _\" and \"bool\"\\n\\nType error in application: operator not of function type\\n\\nOperator:  Patient e :: bool\\nOperand:   x :: ??\\'a\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_64_1\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  KinaseInhibitor :: \"entity \u21d2 bool\"\\n  Mutations :: \"entity \u21d2 bool\"\\n  Pathway :: \"entity \u21d2 bool\"\\n  PI3KAKT :: \"entity \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  In :: \"event \u21d2 entity \u21d2 entity \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 bool\"\\n  Proliferation :: \"event \u21d2 bool\"\\n  Survival :: \"event \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  ProgressionFreeSurvival :: \"entity \u21d2 bool\"\\n  Patients :: \"entity \u21d2 bool\"\\n  PIK3CAMutated :: \"entity \u21d2 bool\"\\n  HRPositive :: \"entity \u21d2 bool\"\\n  HER2Negative :: \"entity \u21d2 bool\"\\n  BreastCancer :: \"entity \u21d2 bool\"\\n  ReceivedEndocrineTherapy :: \"entity \u21d2 bool\"\\n  Previously :: \"entity \u21d2 bool\"\\n  Prolonged :: \"event \u21d2 bool\"\\n  Among :: \"event \u21d2 entity \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation Sentence: A kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival. *)\\naxiomatization where\\n  explanation_sentence: \"\u2203x y z e. KinaseInhibitor x \u2227 Mutations y \u2227 Pathway z \u2227 PI3KAKT z \u2227 Target e \u2227 In e y z \u2227 Inhibit e \u2227 Proliferation e \u2227 Survival e\"\\n\\n(* Premise Sentence: Treatment with alpelisib\u2013fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously. *)\\naxiomatization where\\n  premise_sentence: \"\u2203x y z e. Treatment x \u2227 ProgressionFreeSurvival y \u2227 Patients z \u2227 PIK3CAMutated z \u2227 HRPositive z \u2227 HER2Negative z \u2227 BreastCancer z \u2227 ReceivedEndocrineTherapy z \u2227 Previously z \u2227 Prolonged e \u2227 Among e y z\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Patients x \u2227 ReceivedEndocrineTherapy x\"\\n  (* Hypothesis: A patient has previously received endocrine therapy. *)\\n shows \"\u2203x y e. Patient x \u2227 EndocrineTherapy y \u2227 Received e \u2227 Patient e x \u2227 Therapy e y \u2227 Previously e\"\\nproof -\\n  (* From the premise, we know that patients have received endocrine therapy. *)\\n  from asm have \"Patients x \u2227 ReceivedEndocrineTherapy x\" <ATP>\\n  (* There is a logical relation Implies(B, C), Implies(treatment with alpelisib\u2013fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, patient is likely less sensitive to chemotherapy) *)\\n  (* We can infer that patients who have received endocrine therapy are likely less sensitive to chemotherapy. *)\\n  then have \"Patient x \u2227 EndocrineTherapy y \u2227 Received e \u2227 Patient e x \u2227 Therapy e y \u2227 Previously e\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival (from Explanatory Sentence 1)\\nB: treatment with alpelisib\u2013fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously (from Explanatory Sentence 2)\\nC: patient is likely less sensitive to chemotherapy (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival, treatment with alpelisib\u2013fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously)\\n--------\\nImplies(B, C)\\nImplies(treatment with alpelisib\u2013fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, patient is likely less sensitive to chemotherapy)\\n--------\\n\\nDerived Implications:\\nImplies(A, C)\\nImplies(using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival))\\n--------\\n'}",
            "2 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_64_2\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  KinaseInhibitor :: \"event \u21d2 bool\"\\n  Target :: \"event \u21d2 entity \u21d2 bool\"\\n  Mutations :: \"entity \u21d2 bool\"\\n  PI3KAKTpathway :: \"entity \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 entity \u21d2 bool\"\\n  Proliferation :: \"entity \u21d2 bool\"\\n  Survival :: \"entity \u21d2 bool\"\\n  AlpelisibFulvestrant :: \"event \u21d2 bool\"\\n  Prolonged :: \"event \u21d2 entity \u21d2 bool\"\\n  ProgressionFreeSurvival :: \"entity \u21d2 bool\"\\n  Patient :: \"entity \u21d2 bool\"\\n  PIK3CAmutated :: \"entity \u21d2 bool\"\\n  HRpositive :: \"entity \u21d2 bool\"\\n  HER2negative :: \"entity \u21d2 bool\"\\n  AdvancedBreastCancer :: \"entity \u21d2 bool\"\\n  ReceivedEndocrineTherapy :: \"event \u21d2 entity \u21d2 bool\"\\n  LessSensitive :: \"entity \u21d2 entity \u21d2 bool\"\\n  Chemotherapy :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival. *)\\naxiomatization where\\n  explanation_1: \"\u2200e. KinaseInhibitor e \u27f6 Target e Mutations \u2227 Target e PI3KAKTpathway \u2227 Inhibit e Proliferation \u2227 Inhibit e Survival\"\\n\\n(* Explanation 2: Treatment with alpelisib\u2013fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously. *)\\naxiomatization where\\n  explanation_2: \"\u2200x e. AlpelisibFulvestrant e \u2227 Prolonged e ProgressionFreeSurvival \u2227 Patient x \u2227 PIK3CAmutated x \u2227 HRpositive x \u2227 HER2negative x \u2227 AdvancedBreastCancer x \u2227 ReceivedEndocrineTherapy e x\"\\n\\n(* Explanation 3: A patient is likely less sensitive to chemotherapy. *)\\naxiomatization where\\n  explanation_3: \"\u2200x. Patient x \u27f6 LessSensitive x Chemotherapy\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Patient x \u2227 ReceivedEndocrineTherapy e x\"\\n  (* Hypothesis: If a patient has previously received endocrine therapy, they may benefit from treatment with alpelisib-fulvestrant to target PIK3CA mutation. *)\\n shows \"\u2203e. BenefitFromTreatment e \u2227 Target e PIK3CAmutated\"\\nproof -\\n  (* From the premise, we know that the patient has received endocrine therapy. *)\\n  from asm have \"Patient x\" and \"ReceivedEndocrineTherapy e x\" <ATP>\\n  \\n  (* We have the logical relation Implies(B, C), which states that treatment with alpelisib-fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously implies that the patient is likely less sensitive to chemotherapy. *)\\n  (* This implies that if a patient benefits from treatment with alpelisib-fulvestrant, they are likely less sensitive to chemotherapy. *)\\n  \\n  (* We also have the derived implication Implies(Not(C), Not(A)), which states that if the patient is not likely less sensitive to chemotherapy, then using a kinase inhibitor may not target mutations in the PI3K/AKT pathway and inhibit proliferation and survival. *)\\n  (* Therefore, if a patient benefits from treatment with alpelisib-fulvestrant, they are likely sensitive to chemotherapy. *)\\n  \\n  (* Combining the above two implications, we can infer that if a patient benefits from treatment with alpelisib-fulvestrant, using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival. *)\\n  \\n  (* This aligns with the logical proposition A: using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival. *)\\n  \\n  (* Therefore, we can conclude that there exists an event e where the patient benefits from treatment and the target is PIK3CA mutated. *)\\n  then have \"\u2203e. BenefitFromTreatment e \u2227 Target e PIK3CAmutated\" <ATP>\\n  \\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival\\nB: treatment with alpelisib-fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously\\nC: patient is likely less sensitive to chemotherapy\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival, treatment with alpelisib-fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously)\\n--------\\nImplies(B, C)\\nImplies(treatment with alpelisib-fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, patient is likely less sensitive to chemotherapy)\\n--------\\n\\nDerived Implications:\\nImplies(A, C)\\nImplies(using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival))\\n--------\\n'}",
            "3 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_64_3\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  KinaseInhibitor :: \"event \u21d2 bool\"\\n  Target :: \"event \u21d2 entity \u21d2 bool\"\\n  Mutations :: \"entity \u21d2 bool\"\\n  PI3K_AKT_pathway :: \"entity \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 entity \u21d2 bool\"\\n  Proliferation :: \"entity \u21d2 bool\"\\n  Survival :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  Alpelisib :: \"entity \u21d2 bool\"\\n  Fulvestrant :: \"entity \u21d2 bool\"\\n  ProgressionFreeSurvival :: \"entity \u21d2 bool\"\\n  Patient :: \"entity \u21d2 bool\"\\n  PIK3CA_mutated :: \"entity \u21d2 bool\"\\n  HR_positive :: \"entity \u21d2 bool\"\\n  HER2_negative :: \"entity \u21d2 bool\"\\n  AdvancedBreastCancer :: \"entity \u21d2 bool\"\\n  ReceivedEndocrineTherapy :: \"event \u21d2 entity \u21d2 bool\"\\n  Prolonged :: \"event \u21d2 entity \u21d2 bool\"\\n  LessSensitive :: \"entity \u21d2 entity \u21d2 bool\"\\n  Chemotherapy :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival. *)\\naxiomatization where\\n  explanation_1: \"\u2200e. KinaseInhibitor e \u27f6 Target e Mutations \u2227 Target e PI3K_AKT_pathway \u2227 Inhibit e Proliferation \u2227 Inhibit e Survival\"\\n\\n(* Explanation 2: Treatment with alpelisib\u2013fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously. *)\\naxiomatization where\\n  explanation_2: \"\u2200x e. Patient x \u2227 PIK3CA_mutated x \u2227 HR_positive x \u2227 HER2_negative x \u2227 AdvancedBreastCancer x \u2227 ReceivedEndocrineTherapy e x \u27f6 Prolonged e x \u2227 ProgressionFreeSurvival x\"\\n\\n(* Explanation 3: A patient is likely less sensitive to chemotherapy. *)\\naxiomatization where\\n  explanation_3: \"\u2200x. Patient x \u27f6 LessSensitive x Chemotherapy\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Patient x \u2227 ReceivedEndocrineTherapy e x\"\\n  (* Hypothesis: If a patient has previously received endocrine therapy, they may benefit from treatment with alpelisib-fulvestrant to target PIK3CA mutation. *)\\n shows \"\u2203e. BenefitFromTreatment e \u2227 Target e PIK3CA_mutated\"\\nproof -\\n  (* From the premise, we know that the patient has received endocrine therapy. *)\\n  from asm have \"Patient x \u2227 ReceivedEndocrineTherapy e x\" <ATP>\\n  (* There is a logical relation Implies(B, C), Implies(treatment with alpelisib-fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, patient is likely less sensitive to chemotherapy) *)\\n  (* We can infer that the patient is likely less sensitive to chemotherapy. *)\\n  from explanation_2 and asm have \"Patient x \u2227 PIK3CA_mutated x \u2227 HR_positive x \u2227 HER2_negative x \u2227 AdvancedBreastCancer x \u2227 Prolonged e x \u2227 ProgressionFreeSurvival x\" for some e <ATP>\\n  from explanation_3 have \"Patient x \u27f6 LessSensitive x Chemotherapy\" <ATP>\\n  (* Since the patient is less sensitive to chemotherapy, they may benefit from the treatment with alpelisib-fulvestrant. *)\\n  then have \"BenefitFromTreatment e\" <ATP>\\n  (* The treatment targets PIK3CA mutation. *)\\n  from explanation_1 have \"KinaseInhibitor e \u27f6 Target e PIK3CA_mutated\" <ATP>\\n  then have \"Target e PIK3CA_mutated\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival\\nB: treatment with alpelisib-fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously\\nC: patient is likely less sensitive to chemotherapy\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival, treatment with alpelisib-fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously)\\n--------\\nImplies(B, C)\\nImplies(treatment with alpelisib-fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, patient is likely less sensitive to chemotherapy)\\n--------\\n\\nDerived Implications:\\nImplies(A, C)\\nImplies(using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival))\\n--------\\n'}",
            "4 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_64_4\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  KinaseInhibitor :: \"event \u21d2 bool\"\\n  Mutations :: \"(entity \u21d2 bool) \u21d2 bool\"\\n  PI3K_AKT_pathway :: \"entity \u21d2 bool\"\\n  Target :: \"event \u21d2 (entity \u21d2 bool) \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 entity \u21d2 bool\"\\n  Proliferation :: \"entity \u21d2 bool\"\\n  Survival :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 event \u21d2 bool\"\\n  AlpelisibFulvestrant :: \"entity \u21d2 bool\"\\n  ProgressionFreeSurvival :: \"entity \u21d2 bool\"\\n  Patient :: \"entity \u21d2 bool\"\\n  PIK3CA_mutated :: \"entity \u21d2 bool\"\\n  HR_positive :: \"entity \u21d2 bool\"\\n  HER2_negative :: \"entity \u21d2 bool\"\\n  AdvancedBreastCancer :: \"entity \u21d2 bool\"\\n  ReceivedEndocrineTherapy :: \"event \u21d2 entity \u21d2 bool\"\\n  Prolonged :: \"event \u21d2 (entity \u21d2 bool) \u21d2 bool\"\\n  LessSensitive :: \"entity \u21d2 entity \u21d2 bool\"\\n  Chemotherapy :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival. *)\\naxiomatization where\\n  explanation_1: \"\u2200e. KinaseInhibitor e \u27f6 Target e (Mutations PI3K_AKT_pathway) \u2227 Inhibit e Proliferation \u2227 Inhibit e Survival\"\\n\\n(* Explanation 2: Treatment with alpelisib\u2013fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously. *)\\naxiomatization where\\n  explanation_2: \"\u2200x e. Patient x \u2227 PIK3CA_mutated x \u2227 HR_positive x \u2227 HER2_negative x \u2227 AdvancedBreastCancer x \u2227 ReceivedEndocrineTherapy e x \u27f6 Prolonged e ProgressionFreeSurvival\"\\n\\n(* Explanation 3: A patient is likely less sensitive to chemotherapy. *)\\naxiomatization where\\n  explanation_3: \"\u2200x. Patient x \u27f6 LessSensitive x Chemotherapy\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Patient x \u2227 ReceivedEndocrineTherapy e x\"\\n  (* Hypothesis: If a patient has previously received endocrine therapy, they may benefit from treatment with alpelisib-fulvestrant to target PIK3CA mutation. *)\\n shows \"\u2203e. BenefitFromTreatment e \u2227 Target e (PIK3CA mutation)\"\\nproof -\\n  (* From the premise, we know that the patient x has received endocrine therapy e. *)\\n  from asm have \"Patient x \u2227 ReceivedEndocrineTherapy e x\" <ATP>\\n  (* There is a logical relation Implies(B, C), Implies(treatment with alpelisib-fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, patient is likely less sensitive to chemotherapy) *)\\n  (* We can infer that the patient who received endocrine therapy is likely less sensitive to chemotherapy. *)\\n  then have \"Patient x \u2227 LessSensitive x Chemotherapy\" <ATP>\\n  (* There is a logical relation Implies(Not(C), Not(A)), Implies(Not(patient is likely less sensitive to chemotherapy), Not(using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival)) *)\\n  (* Since the patient is less sensitive to chemotherapy, we can infer that using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival. *)\\n  then have \"Target e (Mutations PI3K_AKT_pathway) \u2227 Inhibit e Proliferation \u2227 Inhibit e Survival\" for e <ATP>\\n  (* We know that the treatment with alpelisib-fulvestrant is beneficial for patients with PIK3CA mutation. *)\\n  then have \"BenefitFromTreatment e \u2227 Target e (Mutations PI3K_AKT_pathway)\" for e <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival\\nB: treatment with alpelisib-fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously\\nC: patient is likely less sensitive to chemotherapy\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival, treatment with alpelisib-fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously)\\n--------\\nImplies(B, C)\\nImplies(treatment with alpelisib-fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, patient is likely less sensitive to chemotherapy)\\n--------\\n\\nDerived Implications:\\nImplies(A, C)\\nImplies(using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival))\\n--------\\n'}",
            "5 iteration: {'syntactic validity': True, 'error code': '(* From the premise, we know that a patient is likely less sensitive to chemotherapy. *)\\nfrom asm obtain y e where \"Patient x \u2227 LessSensitive e \u2227 Likely e \u2227 To e x\" by sledgehammer', 'solving time': 89.80598282814026, 'proof tactics': [], 'code': 'theory clinical_64_5\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  LessSensitive :: \"event \u21d2 bool\"\\n  Likely :: \"event \u21d2 bool\"\\n  To :: \"event \u21d2 entity \u21d2 bool\"\\n  Received :: \"event \u21d2 bool\"\\n  EndocrineTherapy :: \"event \u21d2 bool\"\\n  Previously :: \"event \u21d2 bool\"\\n\\n(* Explanation 3: A patient is likely less sensitive to chemotherapy. *)\\naxiomatization where\\n  explanation_3: \"\u2203x e. Patient x \u2227 LessSensitive e \u2227 Likely e \u2227 To e x\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Patient x\"\\n  (* Hypothesis: A patient has previously received endocrine therapy. *)\\n shows \"\u2203x e. Patient x \u2227 Received e \u2227 Agent e x \u2227 EndocrineTherapy e \u2227 Previously e\"\\nproof -\\n  (* From the premise, we know that a patient is likely less sensitive to chemotherapy. *)\\n  from asm obtain y e where \"Patient x \u2227 LessSensitive e \u2227 Likely e \u2227 To e x\" by <ATP>\\n  (* There is a logical relation Implies(A, C), Implies(using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival, patient is likely less sensitive to chemotherapy) *)\\n  (* We can infer that the patient being less sensitive to chemotherapy is related to using a kinase inhibitor targeting mutations in the PI3K/AKT pathway. *)\\n  then have \"using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival\" by <ATP>\\n  (* However, the hypothesis we aim to prove is about a patient who has previously received endocrine therapy. *)\\n  (* There is a derived implication Implies(Not(C), Not(A)), Implies(Not(patient is likely less sensitive to chemotherapy), Not(using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival)) *)\\n  (* Since the patient is less sensitive to chemotherapy, it does not directly imply that they have received endocrine therapy. *)\\n  (* Therefore, we cannot directly infer the hypothesis from the given information. *)\\n  (* The proof cannot be completed with the provided information. *)\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival\\nB: treatment with alpelisib-fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously\\nC: patient is likely less sensitive to chemotherapy\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival, treatment with alpelisib-fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously)\\n--------\\nImplies(B, C)\\nImplies(treatment with alpelisib-fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, patient is likely less sensitive to chemotherapy)\\n--------\\n\\nDerived Implications:\\nImplies(A, C)\\nImplies(using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival))\\n--------\\n'}",
            "6 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_64_6\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  ChemotherapySensitive :: \"entity \u21d2 bool\"\\n  Less :: \"entity \u21d2 bool\"\\n  Is :: \"entity \u21d2 bool\"\\n  Agent :: \"entity \u21d2 entity \u21d2 bool\"\\n  MoreLikely :: \"entity \u21d2 bool\"\\n  Previously :: \"entity \u21d2 bool\"\\n  Receive :: \"entity \u21d2 bool\"\\n  EndocrineTherapy :: \"entity \u21d2 bool\"\\n  Exhibit :: \"entity \u21d2 bool\"\\n  ReducedSensitivity :: \"entity \u21d2 bool\"\\n  Chemotherapy :: \"entity \u21d2 bool\"\\n  BenefitFrom :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  AlpelisibFulvestrant :: \"entity \u21d2 bool\"\\n  Target :: \"entity \u21d2 entity \u21d2 bool\"\\n  PIK3CA_mutation :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: A patient who is less sensitive to chemotherapy is more likely to have previously received endocrine therapy. *)\\naxiomatization where\\n  explanation_1: \"\u2200x y z e. Patient x \u2227 ChemotherapySensitive y \u2227 Less y \u2227 Is e \u2227 Agent e x \u2227 Patient y x \u2227 MoreLikely z \u2227 Previously z \u2227 Receive z \u2227 Agent x z \u2227 Patient z\"\\n\\n(* Explanation 2: Patients who have received endocrine therapy are more likely to exhibit reduced sensitivity to chemotherapy. *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z e. Patient x \u2227 EndocrineTherapy y \u2227 Receive e \u2227 Agent e x \u2227 Patient y x \u2227 MoreLikely z \u2227 Exhibit z \u2227 ReducedSensitivity z \u2227 Chemotherapy z\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patient x \u2227 EndocrineTherapy y \u2227 Receive e \u2227 Agent x e \u2227 Patient y x \u2227 Previously y\"\\n  (* Hypothesis: If a patient has previously received endocrine therapy, they may benefit from treatment with alpelisib-fulvestrant to target PIK3CA mutation. *)\\n  shows \"\u2203x y z e. Patient x \u2227 EndocrineTherapy y \u2227 Receive e \u2227 Agent x e \u2227 Patient y e \u2227 Previously e \u2227 BenefitFrom z \u2227 Treatment z \u2227 AlpelisibFulvestrant z \u2227 Target z PIK3CA_mutation\"\\nproof -\\n  (* From the premise, we can get known information about the patient, endocrine therapy, and receiving treatment. *)\\n  from asm have \"Patient x \u2227 EndocrineTherapy y \u2227 Receive e \u2227 Agent x e \u2227 Patient y x \u2227 Previously y\" <ATP>\\n  (* There is a logical relation Implies(C, D), Implies(patient has received endocrine therapy, patient exhibits reduced sensitivity to chemotherapy) *)\\n  (* Both C and D are from explanatory sentence 2, we can infer ReducedSensitivity. *)\\n  then have \"Patient x \u2227 EndocrineTherapy y \u2227 Receive e \u2227 Agent x e \u2227 Patient y e \u2227 Previously e \u2227 BenefitFrom z \u2227 Treatment z \u2227 AlpelisibFulvestrant z \u2227 Target z PIK3CA_mutation\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: patient is less sensitive to chemotherapy\\nB: patient has previously received endocrine therapy\\nC: patient has received endocrine therapy\\nD: patient exhibits reduced sensitivity to chemotherapy\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(patient is less sensitive to chemotherapy, patient has previously received endocrine therapy)\\n--------\\nImplies(C, D)\\nImplies(patient has received endocrine therapy, patient exhibits reduced sensitivity to chemotherapy)\\n--------\\n\\nDerived Implications:\\n'}",
            "7 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_64_7\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  ChemotherapySensitivity :: \"entity \u21d2 bool\"\\n  Less :: \"entity \u21d2 bool\"\\n  SensitiveToChemotherapy :: \"entity \u21d2 entity \u21d2 bool\"\\n  Likely :: \"entity \u21d2 bool\"\\n  PreviouslyReceivedEndocrineTherapy :: \"entity \u21d2 entity \u21d2 bool\"\\n  Patients :: \"entity \u21d2 bool\"\\n  EndocrineTherapy :: \"entity \u21d2 bool\"\\n  Receive :: \"entity \u21d2 bool\"\\n  Exhibit :: \"entity \u21d2 bool\"\\n  ReducedSensitivityToChemotherapy :: \"entity \u21d2 entity \u21d2 bool\"\\n  Target :: \"event \u21d2 entity \u21d2 bool\"\\n  PIK3CAMutation :: \"entity \u21d2 bool\"\\n  BenefitFrom :: \"entity \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: A patient who is less sensitive to chemotherapy is more likely to have previously received endocrine therapy. *)\\naxiomatization where\\n  explanation_1: \"\u2200x y z. Patient x \u2227 ChemotherapySensitivity y \u2227 Less y \u2227 SensitiveToChemotherapy x y \u2227 Likely z \u2227 PreviouslyReceivedEndocrineTherapy x z\"\\n\\n(* Explanation 2: Patients who have received endocrine therapy are more likely to exhibit reduced sensitivity to chemotherapy. *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z. Patients x \u2227 EndocrineTherapy y \u2227 Receive x \u2227 Patient x y \u2227 Likely z \u2227 Exhibit x \u2227 ReducedSensitivityToChemotherapy x z\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Patient x \u2227 EndocrineTherapy y \u2227 Receive e \u2227 Agent e x \u2227 Patient e y \u2227 PreviouslyReceivedEndocrineTherapy e z \u2227 Target e z \u2227 PIK3CAMutation z\"\\n  (* Hypothesis: If a patient has previously received endocrine therapy, they may benefit from treatment with alpelisib-fulvestrant to target PIK3CA mutation. *)\\n shows \"\u2203x y z e. Patient x \u2227 EndocrineTherapy y \u2227 Receive e \u2227 Agent e x \u2227 Patient e y \u2227 PreviouslyReceivedEndocrineTherapy e z \u2227 Target e z \u2227 PIK3CAMutation z \u2227 BenefitFrom x z\"\\nproof -\\n  (* From the premise, we can extract the information about the patient, endocrine therapy, receiving, agent, target, and PIK3CA mutation. *)\\n  from asm have \"Patient x \u2227 EndocrineTherapy y \u2227 Receive e \u2227 Agent e x \u2227 Patient e y \u2227 PreviouslyReceivedEndocrineTherapy e z \u2227 Target e z \u2227 PIK3CAMutation z\" <ATP>\\n  (* There are two relevant explanatory sentences that can be used to infer the hypothesis. *)\\n  (* Explanation 1: A patient who is less sensitive to chemotherapy is more likely to have previously received endocrine therapy. *)\\n  (* Explanation 2: Patients who have received endocrine therapy are more likely to exhibit reduced sensitivity to chemotherapy. *)\\n  (* We can use the logical relations to connect the premises and the hypothesis. *)\\n  (* Implies(A, B), Implies(patient is less sensitive to chemotherapy, patient has previously received endocrine therapy) *)\\n  (* Implies(C, D), Implies(patient has received endocrine therapy, patient exhibits reduced sensitivity to chemotherapy) *)\\n  (* From the premise, we have Patient x, EndocrineTherapy y, and PreviouslyReceivedEndocrineTherapy e z. *)\\n  (* Using Implies(A, B), we can infer that the patient has previously received endocrine therapy. *)\\n  then have \"BenefitFrom x z\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: patient is less sensitive to chemotherapy\\nB: patient has previously received endocrine therapy\\nC: patient has received endocrine therapy\\nD: patient exhibits reduced sensitivity to chemotherapy\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(patient is less sensitive to chemotherapy, patient has previously received endocrine therapy)\\n--------\\nImplies(C, D)\\nImplies(patient has received endocrine therapy, patient exhibits reduced sensitivity to chemotherapy)\\n--------\\n\\nDerived Implications:\\n'}",
            "8 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_64_8\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  LessSensitive :: \"entity \u21d2 bool\"\\n  Chemotherapy :: \"entity \u21d2 bool\"\\n  Receive :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  EndocrineTherapy :: \"entity \u21d2 bool\"\\n  MoreLikely :: \"entity \u21d2 bool\"\\n  BenefitFrom :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  AlpelisibFulvestrant :: \"entity \u21d2 bool\"\\n  Target :: \"entity \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: A patient who is less sensitive to chemotherapy is more likely to have previously received endocrine therapy. *)\\naxiomatization where\\n  explanation_1: \"\u2200x y z e. Patient x \u2227 LessSensitive y \u2227 Chemotherapy z \u2227 Receive e \u2227 Agent e x \u2227 Patient x y \u2227 EndocrineTherapy y \u2227 MoreLikely x (have previously received endocrine therapy)\"\\n\\n(* Explanation 2: Patients who have received endocrine therapy are more likely to exhibit reduced sensitivity to chemotherapy. *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z e. Patient x \u2227 EndocrineTherapy y \u2227 Receive e \u2227 Agent e x \u2227 Patient x y \u2227 MoreLikely x (exhibit reduced sensitivity to chemotherapy)\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Patient x \u2227 EndocrineTherapy y\"\\n  (* Hypothesis: If a patient has previously received endocrine therapy, they may benefit from treatment with alpelisib-fulvestrant to target PIK3CA mutation. *)\\n shows \"\u2203x y z e. Patient x \u2227 EndocrineTherapy y \u2227 Receive e \u2227 Agent e x \u2227 Patient x y \u2227 Previously e \u2227 BenefitFrom z \u2227 Treatment z \u2227 AlpelisibFulvestrant z \u2227 Target z (PIK3CA mutation)\"\\nproof -\\n  (* From the premise, we have the information that the patient x has received endocrine therapy y. *)\\n  from asm have \"Patient x \u2227 EndocrineTherapy y\" <ATP>\\n  (* We can use the logical relation Implies(C, D), which states that if a patient has received endocrine therapy, they exhibit reduced sensitivity to chemotherapy. *)\\n  (* Since the patient has received endocrine therapy, we can infer that they exhibit reduced sensitivity to chemotherapy. *)\\n  then have \"Patient x \u2227 EndocrineTherapy y \u2227 MoreLikely x (exhibit reduced sensitivity to chemotherapy)\" <ATP>\\n  (* The hypothesis involves the concept of benefiting from treatment with alpelisib-fulvestrant to target PIK3CA mutation. *)\\n  (* We can introduce the concept of benefiting from treatment based on the given information. *)\\n  then have \"Patient x \u2227 EndocrineTherapy y \u2227 BenefitFrom z\" <ATP>\\n  (* Additionally, the hypothesis includes the treatment with alpelisib-fulvestrant to target PIK3CA mutation. *)\\n  (* We can introduce the treatment with alpelisib-fulvestrant based on the hypothesis. *)\\n  then have \"Patient x \u2227 EndocrineTherapy y \u2227 BenefitFrom z \u2227 Treatment z \u2227 AlpelisibFulvestrant z\" <ATP>\\n  (* Finally, the hypothesis involves targeting the PIK3CA mutation. *)\\n  (* We can introduce the targeting of PIK3CA mutation based on the hypothesis. *)\\n  then have \"Patient x \u2227 EndocrineTherapy y \u2227 BenefitFrom z \u2227 Treatment z \u2227 AlpelisibFulvestrant z \u2227 Target z (PIK3CA mutation)\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: patient is less sensitive to chemotherapy\\nB: patient has previously received endocrine therapy\\nC: patient has received endocrine therapy\\nD: patient exhibits reduced sensitivity to chemotherapy\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(patient is less sensitive to chemotherapy, patient has previously received endocrine therapy)\\n--------\\nImplies(C, D)\\nImplies(patient has received endocrine therapy, patient exhibits reduced sensitivity to chemotherapy)\\n--------\\n\\nDerived Implications:\\n'}",
            "9 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 10.44041919708252, 'proof tactics': ['Type unification failed: Clash of types \"_ \\\\<Rightarrow> _\" and \"entity\"\\n\\nType error in application: incompatible operand type\\n\\nOperator:  Treatment e :: entity \\\\<Rightarrow> bool\\nOperand:   AlpelisibFulvestrant :: entity \\\\<Rightarrow> bool\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_64_9\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  LessSensitiveToChemotherapy :: \"entity \u21d2 bool\"\\n  MoreLikely :: \"event \u21d2 bool\"\\n  ReceivedEndocrineTherapy :: \"event \u21d2 entity \u21d2 bool\"\\n  Exhibit :: \"event \u21d2 bool\"\\n  ReducedSensitivityToChemotherapy :: \"entity \u21d2 bool\"\\n  BenefitFrom :: \"event \u21d2 bool\"\\n  Treatment :: \"event \u21d2 entity \u21d2 bool\"\\n  Target :: \"event \u21d2 entity \u21d2 bool\"\\n  AlpelisibFulvestrant :: \"entity \u21d2 bool\"\\n  PIK3CA_mutation :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: A patient who is less sensitive to chemotherapy is more likely to have previously received endocrine therapy *)\\naxiomatization where\\n  explanation_1: \"\u2203x e. Patient x \u2227 LessSensitiveToChemotherapy x \u2227 MoreLikely e \u2227 ReceivedEndocrineTherapy e x\"\\n\\n(* Explanation 2: Patients who have received endocrine therapy are more likely to exhibit reduced sensitivity to chemotherapy *)\\naxiomatization where\\n  explanation_2: \"\u2200x e. Patient x \u2227 ReceivedEndocrineTherapy e x \u27f6 MoreLikely e \u2227 Exhibit e \u2227 ReducedSensitivityToChemotherapy x\"\\n\\ntheorem hypothesis:\\n assumes asm: \"Patient x \u2227 ReceivedEndocrineTherapy e x\"\\n (* Hypothesis: If a patient has previously received endocrine therapy, they may benefit from treatment with alpelisib-fulvestrant to target PIK3CA mutation *)\\n shows \"BenefitFrom e \u2227 Treatment e AlpelisibFulvestrant \u2227 Target e PIK3CA_mutation\"\\nproof -\\n  (* From the premise, we can get known information about the patient and endocrine therapy. *)\\n  from asm have \"Patient x \u2227 ReceivedEndocrineTherapy e x\" <ATP>\\n  (* There are two relevant explanatory sentences to consider. *)\\n  (* Explanation 1: A patient who is less sensitive to chemotherapy is more likely to have previously received endocrine therapy *)\\n  (* There is a logical relation Implies(A, B), Implies(patient is less sensitive to chemotherapy, patient has previously received endocrine therapy) *)\\n  (* A is less sensitive to chemotherapy, B is previously received endocrine therapy. *)\\n  (* We have Patient x and ReceivedEndocrineTherapy e x, so we can infer LessSensitiveToChemotherapy x. *)\\n  then have \"Patient x \u2227 LessSensitiveToChemotherapy x \u2227 MoreLikely e\" <ATP>\\n  (* Explanation 2: Patients who have received endocrine therapy are more likely to exhibit reduced sensitivity to chemotherapy *)\\n  (* There is a logical relation Implies(C, D), Implies(patient has received endocrine therapy, patient exhibits reduced sensitivity to chemotherapy) *)\\n  (* C is ReceivedEndocrineTherapy e x, D is ReducedSensitivityToChemotherapy x. *)\\n  (* We already have Patient x and ReceivedEndocrineTherapy e x, so we can infer ReducedSensitivityToChemotherapy x. *)\\n  then have \"Patient x \u2227 ReducedSensitivityToChemotherapy x \u2227 MoreLikely e \u2227 Exhibit e\" <ATP>\\n  (* The hypothesis states that the patient may benefit from treatment with alpelisib-fulvestrant to target PIK3CA mutation. *)\\n  (* We can directly infer the hypothesis from the information we have. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: patient is less sensitive to chemotherapy\\nB: patient has previously received endocrine therapy\\nC: patient has received endocrine therapy\\nD: patient exhibits reduced sensitivity to chemotherapy\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(patient is less sensitive to chemotherapy, patient has previously received endocrine therapy)\\n--------\\nImplies(C, D)\\nImplies(patient has received endocrine therapy, patient exhibits reduced sensitivity to chemotherapy)\\n--------\\n\\nDerived Implications:\\n'}",
            "10 iteration: {'syntactic validity': True, 'error code': '(* The hypothesis states that if a patient has previously received endocrine therapy, they may benefit from treatment with alpelisib-fulvestrant to target PIK3CA mutation. *)\\n(* We can infer that the patient x benefits from the treatment with alpelisib-fulvestrant to target PIK3CA mutation. *)\\nthen have \"Patient x \u2227 Benefit e2 \u2227 Treatment e2 \u2227 AlpelisibFulvestrant e2 \u2227 Target e2 PIK3CA\" for e2 sledgehammer', 'solving time': 134.65784883499146, 'proof tactics': [], 'code': 'theory clinical_64_10\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  LessSensitive :: \"event \u21d2 bool\"\\n  Chemotherapy :: \"event \u21d2 bool\"\\n  MoreLikely :: \"event \u21d2 bool\"\\n  Received :: \"entity \u21d2 event \u21d2 bool\"\\n  EndocrineTherapy :: \"event \u21d2 bool\"\\n  Patients :: \"entity \u21d2 bool\"\\n  Exhibit :: \"event \u21d2 bool\"\\n  ReducedSensitivity :: \"event \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n  Treatment :: \"event \u21d2 bool\"\\n  AlpelisibFulvestrant :: \"event \u21d2 bool\"\\n  Target :: \"event \u21d2 entity \u21d2 bool\"\\n  PIK3CA :: \"entity\"\\n\\n(* Explanation 1: A patient who is less sensitive to chemotherapy is more likely to have previously received endocrine therapy *)\\naxiomatization where\\n  explanation_1: \"\u2203x e1 e2. Patient x \u2227 LessSensitive e1 \u2227 Chemotherapy e1 \u2227 MoreLikely e2 \u2227 Received x e2 \u2227 EndocrineTherapy e2\"\\n\\n(* Explanation 2: Patients who have received endocrine therapy are more likely to exhibit reduced sensitivity to chemotherapy *)\\naxiomatization where\\n  explanation_2: \"\u2200x e1 e2. Patients x \u2227 Received x e1 \u2227 EndocrineTherapy e1 \u2227 MoreLikely e2 \u2227 Exhibit e2 \u2227 ReducedSensitivity e2 \u2227 Chemotherapy e2\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Patient x \u2227 EndocrineTherapy e1\"\\n  (* Hypothesis: If a patient has previously received endocrine therapy, they may benefit from treatment with alpelisib-fulvestrant to target PIK3CA mutation *)\\n shows \"\u2203x e1 e2. Patient x \u2227 EndocrineTherapy e1 \u2227 Benefit e2 \u2227 Treatment e2 \u2227 AlpelisibFulvestrant e2 \u2227 Target e2 PIK3CA \u2227 Received x e1 \u2227 Agent e1 x\"\\nproof -\\n  (* From the premise, we know that the patient x has received endocrine therapy. *)\\n  from asm have \"Patient x \u2227 EndocrineTherapy e1\" <ATP>\\n  (* We have the logical relation Implies(C, D), which states that if a patient has received endocrine therapy, they exhibit reduced sensitivity to chemotherapy. *)\\n  (* Since the patient has received endocrine therapy, we can infer that they exhibit reduced sensitivity to chemotherapy. *)\\n  then have \"Patient x \u2227 ReducedSensitivity e2 \u2227 Chemotherapy e2\" for e2 <ATP>\\n  (* From explanatory sentence 2, we have the information that patients who have received endocrine therapy are more likely to exhibit reduced sensitivity to chemotherapy. *)\\n  (* Therefore, we can conclude that the patient x exhibits reduced sensitivity to chemotherapy. *)\\n  then have \"Patient x \u2227 ReducedSensitivity e2\" for e2 <ATP>\\n  (* The hypothesis states that if a patient has previously received endocrine therapy, they may benefit from treatment with alpelisib-fulvestrant to target PIK3CA mutation. *)\\n  (* We can infer that the patient x benefits from the treatment with alpelisib-fulvestrant to target PIK3CA mutation. *)\\n  then have \"Patient x \u2227 Benefit e2 \u2227 Treatment e2 \u2227 AlpelisibFulvestrant e2 \u2227 Target e2 PIK3CA\" for e2 <ATP>\\n  (* Finally, we know that the patient x has received endocrine therapy. *)\\n  then have \"Received x e1 \u2227 Agent e1 x\" <ATP>\\n  (* Combining all the information, we can conclude that there exists x, e1, and e2 such that the patient x benefits from the treatment with alpelisib-fulvestrant to target PIK3CA mutation. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: patient is less sensitive to chemotherapy\\nB: patient has previously received endocrine therapy\\nC: patient has received endocrine therapy\\nD: patient exhibits reduced sensitivity to chemotherapy\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(patient is less sensitive to chemotherapy, patient has previously received endocrine therapy)\\n--------\\nImplies(C, D)\\nImplies(patient has received endocrine therapy, patient exhibits reduced sensitivity to chemotherapy)\\n--------\\n\\nDerived Implications:\\n'}"
        ]
    }
}